These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Gremlin-1 is an inhibitor of macrophage migration inhibitory factor and attenuates atherosclerotic plaque growth in ApoE-/- Mice. Müller I; Schönberger T; Schneider M; Borst O; Ziegler M; Seizer P; Leder C; Müller K; Lang M; Appenzeller F; Lunov O; Büchele B; Fahrleitner M; Olbrich M; Langer H; Geisler T; Lang F; Chatterjee M; de Boer JF; Tietge UJ; Bernhagen J; Simmet T; Gawaz M J Biol Chem; 2013 Nov; 288(44):31635-45. PubMed ID: 24003215 [TBL] [Abstract][Full Text] [Related]
12. Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice. Aono J; Suzuki J; Iwai M; Horiuchi M; Nagai T; Nishimura K; Inoue K; Ogimoto A; Okayama H; Higaki J Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1453-9. PubMed ID: 22460554 [TBL] [Abstract][Full Text] [Related]
13. CCR5 facilitates endothelial progenitor cell recruitment and promotes the stabilization of atherosclerotic plaques in ApoE-/- mice. Zhang Z; Dong J; Lobe CG; Gong P; Liu J; Liao L Stem Cell Res Ther; 2015 Mar; 6(1):36. PubMed ID: 25889019 [TBL] [Abstract][Full Text] [Related]
14. AnxA5 reduces plaque inflammation of advanced atherosclerotic lesions in apoE(-/-) mice. Burgmaier M; Schutters K; Willems B; van der Vorst EP; Kusters D; Chatrou M; Norling L; Biessen EA; Cleutjens J; Perretti M; Schurgers LJ; Reutelingsperger CP J Cell Mol Med; 2014 Oct; 18(10):2117-24. PubMed ID: 25214012 [TBL] [Abstract][Full Text] [Related]
15. MiR-188-3p upregulation results in the inhibition of macrophage proinflammatory activities and atherosclerosis in ApoE-deficient mice. Zhang XF; Yang Y; Yang XY; Tong Q Thromb Res; 2018 Nov; 171():55-61. PubMed ID: 30253270 [TBL] [Abstract][Full Text] [Related]
16. Elimination of macrophages drives LXR-induced regression both in initial and advanced stages of atherosclerotic lesion development. van der Stoep M; Li Z; Calpe-Berdiel L; van der Sluis RJ; Saleh P; McKinnon HJ; Smit MJ; Korporaal SJ; Van Berkel TJ; Van Eck M; Hoekstra M Biochem Pharmacol; 2013 Dec; 86(11):1594-602. PubMed ID: 24095721 [TBL] [Abstract][Full Text] [Related]
17. Genetic deletion of LXRα prevents arsenic-enhanced atherosclerosis, but not arsenic-altered plaque composition. Lemaire M; Lemarié CA; Flores Molina M; Guilbert C; Lehoux S; Mann KK Toxicol Sci; 2014 Dec; 142(2):477-88. PubMed ID: 25273567 [TBL] [Abstract][Full Text] [Related]
18. In vivo fluorescence-mediated tomography imaging demonstrates atorvastatin-mediated reduction of lesion macrophages in ApoE-/- mice. Larmann J; Frenzel T; Schmitz M; Hahnenkamp A; Demmer P; Immenschuh S; Tietge UJ; Bremer C; Theilmeier G Anesthesiology; 2013 Jul; 119(1):129-41. PubMed ID: 23559030 [TBL] [Abstract][Full Text] [Related]
19. Deficiency in lymphotoxin β receptor protects from atherosclerosis in apoE-deficient mice. Grandoch M; Feldmann K; Göthert JR; Dick LS; Homann S; Klatt C; Bayer JK; Waldheim JN; Rabausch B; Nagy N; Oberhuber A; Deenen R; Köhrer K; Lehr S; Homey B; Pfeffer K; Fischer JW Circ Res; 2015 Apr; 116(8):e57-68. PubMed ID: 25740843 [TBL] [Abstract][Full Text] [Related]
20. Transgenic CGI-58 expression in macrophages alleviates the atherosclerotic lesion development in ApoE knockout mice. Xie P; Zeng X; Xiao J; Sun B; Yang D Biochim Biophys Acta; 2014 Dec; 1841(12):1683-90. PubMed ID: 25178844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]